E-cadherin frequently displays abundant expression in primary well-differentiated ovarian carcinomas [112–115], while loss or reduced E-cadherin expression is detected in ascites, late stage carcinomas and metastases [116–118], and is predictive of poor overall survival [65, 119]. Here, CDH1 is linked to ovarian carcinoma.